Free Trial

Mirum Pharmaceuticals (MIRM) News Today

Mirum Pharmaceuticals logo
$46.28 -0.78 (-1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$46.26 -0.02 (-0.04%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from Analysts
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus rating of "Buy" by the eleven brokerages that are covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and one has assigned a strong bu
Mirum Pharmaceuticals, Inc. stock logo
Raymond James Financial Inc. Purchases New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Raymond James Financial Inc. acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 256,612 shares of the company's stock, v
Mirum Pharmaceuticals, Inc. stock logo
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 7,879 Shares of Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 7,879 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the sale, the chief operating officer now owns 18,672 shares in the company, valued at approximately $825,489.12. This trade represents a 29.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Mirum Pharmaceuticals, Inc. stock logo
Christopher Peetz Sells 27,279 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares of the company's stock, valued at approximately $6,129,318.61. This trade represents a 16.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $2,554,826.10 in Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 57,606 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. The trade was a 92.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up - Here's Why
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up - Should You Buy?
Mirum Pharmaceuticals, Inc. stock logo
Bank of New York Mellon Corp Has $5.14 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Bank of New York Mellon Corp increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 8.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,328 shares of the company's stock a
Mirum Pharmaceuticals, Inc. stock logo
Connor Clark & Lunn Investment Management Ltd. Acquires 109,585 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 162.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,96
Mirum Pharmaceuticals, Inc. stock logo
Aigen Investment Management LP Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Aigen Investment Management LP acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,742 shares of the company's stock, value
Mirum Pharmaceuticals, Inc. stock logo
Insider Buying: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Purchases 1,335 Shares of Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) Director Patrick J. Heron acquired 1,335 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were purchased at an average price of $45.57 per share, with a total value of $60,835.95. Following the completion of the purchase, the director now owns 163,643 shares in the company, valued at $7,457,211.51. This represents a 0.82 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Mirum Pharmaceuticals, Inc. stock logo
Candriam S.C.A. Sells 78,744 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Candriam S.C.A. trimmed its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 429,731 shares of the company's stock after selli
Mirum Pharmaceuticals, Inc. stock logo
Equities Analysts Issue Forecasts for MIRM FY2025 Earnings
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company
Mirum Pharmaceuticals, Inc. stock logo
Equities Analysts Offer Predictions for MIRM Q3 Earnings
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Mirum Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar expects that the compa
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC Wainwright
HC Wainwright raised their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday.
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% After Earnings Miss
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% Following Weak Earnings
Mirum Pharmaceuticals, Inc. stock logo
Robert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price
Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday.
Mirum Pharmaceuticals price target raised to $55 from $50 at Baird
Evercore ISI Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Brokerages
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have received a consensus recommendation of "Buy" from the eleven research firms that are presently covering the firm, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy rating and one has assign
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals (NASDAQ:MIRM) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPS
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) released its earnings results on Wednesday. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%.
Mirum Pharmaceuticals, Inc. stock logo
Phocas Financial Corp. Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Phocas Financial Corp. trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 85.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,699 shares of the company'
Mirum Pharmaceuticals misses Q4 earnings, stock falls
Mirum Pharmaceuticals reports FY24 EPS ($1.85), consensus ($1.42)
Mirum Pharmaceuticals, Inc. stock logo
Allspring Global Investments Holdings LLC Acquires New Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Allspring Global Investments Holdings LLC purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 9,981 shares of the company's stock, valu
Mirum Pharmaceuticals announces FDA approval for Ctexli tablets
Mirum Pharmaceuticals, Inc. stock logo
HealthInvest Partners AB Has $4.81 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
HealthInvest Partners AB decreased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,692 shares of the comp
FDA approves Mirum treatment for cerebrotendinous xanthomatosis
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Here's Why
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High - Should You Buy?
Mirum Pharmaceuticals, Inc. stock logo
Mirum Pharmaceuticals (MIRM) to Release Quarterly Earnings on Wednesday
Mirum Pharmaceuticals (NASDAQ:MIRM) will be releasing earnings before the market opens on Wednesday, February 26.
Mirum Pharmaceuticals, Inc. stock logo
Empowered Funds LLC Purchases Shares of 33,266 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Empowered Funds LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,266 shares of the company's sto
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. stock logo
SG Americas Securities LLC Has $289,000 Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
SG Americas Securities LLC trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 66.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company
Remove Ads
Get Mirum Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.

MIRM Media Mentions By Week

MIRM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MIRM
News Sentiment

1.33

0.89

Average
Medical
News Sentiment

MIRM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MIRM Articles
This Week

8

4

MIRM Articles
Average Week

Remove Ads
Get Mirum Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:MIRM) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners